COVID-19 Oral Vaccine and Antibody Booster: B. subtilis Spores, Biotechnology Breakthrough by DreamTec
Comunicato Precedente
Comunicato Successivo
B. subtilis is chosen based on its ability to survive human gut microbiome conditions by forming spores. It is also recognized by the U.S. Food and Drug Administration (FDA) as Generally Recognized As Safe (GRAS). As the ability of traditional vaccines is undermined whenever there is a variant, Dr. Kwong revealed, "We made our current constructs in a matter of months, so if needed we can do the same in the future with other possible SARS-CoV-2 variants, such as Omicron."
"We plan to engage with industry partners to conduct pre-clinical studies to evaluate safety concerns for human use," said Dr. Kwong. DreamTec envisions the oral antibody booster being manufactured in forms of capsules which contain billions of B. subtilis spores. The transgenic spores are then released in the small intestine, where a mucosal specific-immune response is generated. This allows for a safe and effective approach to the vaccinated individuals with for adding immune protection against SARS-CoV-2.
Founded by Dr. Kwong Wai Yeung, DreamTec is a biotechnology company which develops cutting-edge biotechnologies including expression of valuable recombinant proteins, RNA, and stem cells cultivation.
Video - https://mma.prnewswire.com/media/1717684/Oral_vaccine_English_v2.mp4
Photo - https://mma.prnewswire.com/media/1717472/Image_1.jpg
Photo - https://mma.prnewswire.com/media/1717473/Image_2.jpg
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom




